Our company

Oviva is founded by Kai Eberhardt, Manuel Baumann and Mark Jenkins.

We employ the first dietitian in Switzerland.

The first person is treated, supported by our app.

We open our first office outside Swiss borders: in London, United Kingdom.

People begin to notice us: we sign our first contracts with a doctor and a health insurance provider in Switzerland, and with the NHS in the United Kingdom.

We complete our first round of funding and receive $800,000.

Oviva already employs more than 50 people.

We also open an office in Potsdam, Germany – our third site.

By the end of this year, we’re already working with roughly 100 doctors and clinics across Europe.

Three’s not enough – so we open our fourth office, this time in Paris, France.

To continue to drive our business forward, we require liquid assets: we complete the Series A financing round and receive $11 million.

We already have 150 employees, treat roughly 50,000 people and work with more than 1000 doctors.

We win first prize at the Forum of Managed Care (FMC) and become recognised as a “Model of Good Practice” by the Swiss Federal Office of Public Health.

We complete another financing round (Series B) at the start of this year and receive $21 million.

Our employees now total 300, roughly 100,000 people have received advice or are still receiving treatment, and we work with more than 5,000 doctors.

In Germany, we reach a milestone and begin our first collaboration with a German health insurer.

We sign our first partnership agreement with a French health insurer.

In September, we complete the Series C financing round and receive $80 million; one of the largest rounds in the European digital health sector.

Our first digital health application (or DiGA), Oviva Direkt for obesity, is included in the DiGA directory of the German Federal Institute for Drugs and Medical Devices (BfArM, Bundesinstitut für Arzneimittel und Medizinprodukte) in October.

We end the year with 600 employees and over 200,000 patients treated. What a year!

Scaling of Oviva’s digital therapeutic product, Oviva Direkt – a German DiGA.

Winner of the 2022 HSJ Partnerships Award for the ‘Most impactful project addressing health inequalities’ for our Type 2 diabetes structured education programme delivered in partnership with NHS North East London. 

Expansion of our range of therapies in Switzerland: Our patients can now also take advantage of our app-guided psychotherapy to improve their health in the long term.

By the end of the year, we had treated more than 300k patients and further expanded our partnerships with doctors, clinics and health insurers throughout Europe.